Page last updated: 2024-09-05

lenalidomide and Diseases of Endocrine System

lenalidomide has been researched along with Diseases of Endocrine System in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Aoki, K; Katayama, A; Kohno, K; Nagao, T; Nishimura, N; Obara, T; Ogawa, R; Shimokawa, S; Taenaka, R; Tsujimoto, A	1
Aotsuka, Y; Kano, H; Kuwabara, S; Mimura, N; Misawa, S; Morooka, M; Nakamura, K; Ohwada, C; Otani, R; Sakaida, E; Sekiguchi, Y; Shibuya, K; Suichi, T; Takeda, Y; Tsukamoto, S	1
Cosiglio, FJ; Ordi-Ros, J	1

Reviews

1 review(s) available for lenalidomide and Diseases of Endocrine System

Article	Year
[Current therapeutic indications of thalidomide and lenalidomide]. Medicina clinica, 2014, Apr-22, Volume: 142, Issue:8 Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; Endocrine System Diseases; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Humans; Immunologic Factors; Inflammation; Lenalidomide; Neoplasms; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Safety-Based Drug Withdrawals; Skin Diseases; Thalidomide; Thrombophilia; Vasculitis	2014

Article

Year

[Current therapeutic indications of thalidomide and lenalidomide].

Medicina clinica, 2014, Apr-22, Volume: 142, Issue:8

Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; Endocrine System Diseases; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Humans; Immunologic Factors; Inflammation; Lenalidomide; Neoplasms; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Safety-Based Drug Withdrawals; Skin Diseases; Thalidomide; Thrombophilia; Vasculitis

2014

Other Studies

2 other study(ies) available for lenalidomide and Diseases of Endocrine System

Article	Year
Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report. Journal of medical case reports, 2022, Aug-18, Volume: 16, Issue:1 Topics: Adult; Antibodies, Monoclonal; Dexamethasone; Endocrine System Diseases; Female; Filgrastim; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Polyneuropathies; Transplantation, Autologous	2022
Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. Internal medicine (Tokyo, Japan), 2022, Volume: 61, Issue:17 Topics: Boron Compounds; Dexamethasone; Endocrine System Diseases; Glycine; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; POEMS Syndrome; Vascular Endothelial Growth Factor A	2022

Article

Year

Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.

Journal of medical case reports, 2022, Aug-18, Volume: 16, Issue:1

Topics: Adult; Antibodies, Monoclonal; Dexamethasone; Endocrine System Diseases; Female; Filgrastim; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Polyneuropathies; Transplantation, Autologous

2022

Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.

Internal medicine (Tokyo, Japan), 2022, Volume: 61, Issue:17

Topics: Boron Compounds; Dexamethasone; Endocrine System Diseases; Glycine; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; POEMS Syndrome; Vascular Endothelial Growth Factor A

2022